Oligonucleotide and Peptide Therapeutics Boston, Cambridge, MA, USA
Dr. Michel Janicot will chair a session (Advances in RNA Therapeutics and Delivery & Emerging Nucleic Acid Development Platforms) at the CHI’s Third Annual Oligonucleotide & Peptide Therapeutics (OPT) conference – Oligonucleotide Discovery and Delivery. Advances in the Development and Delivery of Aptamer, Antisense and RNA Therapeutics. Boston, MA. USA. March 26-28, 2018. During the conference, Dr. Janicot will also present exciting results on InteRNA lead development asset in an oral presentation entitled: INT-1B3 – a chemically-modified microRNA mimic targeting multiple hallmarks of Cancer and representing potential new approach to immunotherapy on March 27, 2018 at 9:30 in the C1M: Oligonucleotide Discovery and Delivery track.